No sabemos si la última respuesta a esta solicitud contiene información o no – si eres Abdul Hai por favor abre una sesión y háznoslo saber.

Brexit

Estamos a la espera de que Abdul Hai lea las últimas respuestas y de que actualice el estado.

Dear European Medicines Agency,

Under the right of access to documents in the EU treaties, as developed in Regulation 1049/2001, I am requesting documents which contain the following information:

Can you publish all information sent to staff in regards to Brexit?

Can you publish any planning documents in regards to Brexit?

Yours faithfully,

Abdul Hai

PF-15, Agencia Europea de Medicamentos

Dear Sir/Madam,
Thank you for contacting the European Medicines Agency.
Please note that this mailbox is not monitored. If you wish to submit requests for information or access to documents, please use the webform by following the link below:
http://www.ema.europa.eu/ema/index.jsp?c...
For more information on ATD please refer to our guide on access to unpublished documents:
http://www.ema.europa.eu/ema/index.jsp?c...
Best regards,
The European Medicines Agency

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines Agency.
________________________________________________________________________

ocultar partes citadas

Abdul Hai dejó un comentario ()

I have asked asktheeu.org for the unique email address for the request. When I get it I will use that instead of my email address. This will mean they will reply to asktheeu.org.

To see if it works. 
 
[1]You can keep up with me on Twitter.

References

Visible links
1. https://twitter.com/AbdulHai23

AskEMA, Agencia Europea de Medicamentos

Dear Sir/Madam

Re: ASK-28403 Brexit received on 13 March 2017

Thank you for submitting your request.

This is an automated response to confirm that we have received your
request; please do not respond to this message.

We endeavour to provide a response to all information enquiries (RFI)
within 2 months according to [1]The European Medicines Agency Code of Good
Administrative Behaviour.

Concerning requests for access to documents (ATD), your enquiry will be
processed according to [2]Regulation (EC) No 1049/2001. .
For more information on ATD please refer to our guide on access to
unpublished documents:
[3]http://www.ema.europa.eu/ema/index.jsp?c...

This automated response is not an acknowledgement of receipt or
registration for the purpose of the ATD process. Such
acknowledgment/registration will be issued separately following
validation.

Should you need to contact us, please always use in the title of your
email, the reference number ASK-28403, which has been allocated to your
request.

Kind regards

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [4]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. http://www.ema.europa.eu/docs/en_GB/docu...
2. http://www.europarl.europa.eu/RegData/PD...
3. http://www.ema.europa.eu/ema/index.jsp?c...
4. http://www.ema.europa.eu/contact

ocultar partes citadas

AskEMA, Agencia Europea de Medicamentos

Re: EMA request reference ASK-28403

Dear Mr Hai,

Thank you for your query of 13 March about Brexit.

EMA currently does not plan to publish information sent to staff or
planning documents relating to its preparedness planning for the
withdrawal of the UK from the EU.

Planning documents and information sent to staff regarding the impact of a
possible exit of the UK from the EU are only indicative. Firm plans can
only be made when the relationship between the UK and the EU has been
clarified. This will be the outcome of negotiations between the EU and the
UK. EMA does not have a role in these negotiations.

Once more information is available on the future relationship between the
UK and the EU and its impact on the Agency, EMA will communicate as
necessary.

I hope this information is helpful.

Best regards,
Elizabeth Scanlan
Please help us to improve our service by giving us your feedback:
[1]https://ec.europa.eu/eusurvey/runner/Ask...

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [2]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

--------------------------------------------------------------------------

Original request: Brexit

Can you publish all information sent to staff in regards to Brexit? Can
you publish any planning documents in regards to Brexit?

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. https://ec.europa.eu/eusurvey/runner/Ask...
2. http://www.ema.europa.eu/contact

ocultar partes citadas

Dear European Medicines Agency,

Please pass this on to the person who reviews confirmatory applications.

I am filing the following confirmatory application with regards to my access to documents request 'Brexit'.

I believe that a blanket decision has been made not to publish information. Some of it should be in the public domain.

Also I note that no legal reasons were given.

A full history of my request and all correspondence is available on the Internet at this address: https://www.asktheeu.org/en/request/brex...

Yours faithfully,

Abdul Hai

PF-15, Agencia Europea de Medicamentos

Dear Sir/Madam,
Thank you for contacting the European Medicines Agency.
Please note that this mailbox is not monitored. If you wish to submit requests for information or access to documents, please use the webform by following the link below:
http://www.ema.europa.eu/ema/index.jsp?c...
For more information on ATD please refer to our guide on access to unpublished documents:
http://www.ema.europa.eu/ema/index.jsp?c...
Best regards,
The European Medicines Agency

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines Agency.
________________________________________________________________________

ocultar partes citadas

Dear European Medicines Agency,

Please pass this on to the person who reviews confirmatory applications.

I am filing the following confirmatory application with regards to my access to documents request 'Brexit'.

I believe that a blanket decision has been made not to publish information. Some of it should be in the public domain.

Also I note that no legal reasons were given.

A full history of my request and all correspondence is available on the Internet at this address: https://www.asktheeu.org/en/request/brex...

Yours faithfully,

Abdul Hai

Agencia Europea de Medicamentos

2 Adjuntos

Delivery has failed to these recipients or groups:

[1]PF-15 ([email address])
There's a problem with the recipient's mailbox. Please try resending the
message. If the problem continues, please contact your helpdesk.

The following organization rejected your message: wv1276.emea.eu.int.

Diagnostic information for administrators:

Generating server: wv1278.emea.eu.int

[email address]
wv1276.emea.eu.int
Remote Server returned '554 5.2.0
STOREDRV.Deliver.Exception:AccessDeniedException; Failed to process
message due to a permanent exception with message This operation is not
supported on a public folder mailbox. AccessDeniedException: This
operation is not supported on a public folder mailbox. [Stage:
CreateSession]'

Original message headers:

Received: from wv1275.emea.eu.int (172.16.91.20) by wv1278.emea.eu.int
(172.16.91.23) with Microsoft SMTP Server (TLS) id 15.0.1263.5; Tue, 28 Mar
2017 09:32:17 +0100
Received: from mail6.bemta5.messagelabs.com (172.16.40.221) by
wv1275.emea.eu.int (172.16.91.20) with Microsoft SMTP Server (TLS) id
15.0.1263.5 via Frontend Transport; Tue, 28 Mar 2017 09:32:17 +0100
Return-Path: <[FOI #4074 email]>
Received: from [85.158.139.211] by server-9.bemta-5.messagelabs.com id 3F/DB-32461-19F1AD85; Tue, 28 Mar 2017 08:32:17 +0000
X-Brightmail-Tracker: H4sIAAAAAAAAA+NgFvrLLMWRWlGSWpSXmKPExsWip60erDtB/la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==
X-Env-Sender: [FOI #4074 email]
X-Msg-Ref: server-7.tower-206.messagelabs.com!1490689936!88836676!1
X-Originating-IP: [46.43.39.83]
X-SpamReason: No, hits=1.6 required=7.0 tests=DEAR_SOMETHING
X-StarScan-Received:
X-StarScan-Version: 9.2.3; banners=-,-,-
X-VirusChecked: Checked
Received: (qmail 43333 invoked from network); 28 Mar 2017 08:32:16 -0000
Received: from mastodon.ukcod.org.uk (HELO mastodon.ukcod.org.uk) (46.43.39.83)
by server-7.tower-206.messagelabs.com with DHE-RSA-AES128-SHA encrypted SMTP; 28 Mar 2017 08:32:16 -0000
Received: from foieu by mastodon.ukcod.org.uk with local (Exim 4.80)
(envelope-from <[FOI #4074 email]>)
id 1csmY3-0003u0-Rt; Tue, 28 Mar 2017 09:32:15 +0100
Date: Tue, 28 Mar 2017 09:32:15 +0100
From: Abdul Hai <[FOI #4074 email]>
To: PF-15 <[email address]>
Message-ID: <[email address]>
Subject: Internal review of access to documents request - Brexit
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: 7bit

References

Visible links
1. mailto:[email address]

Checking again
 
[1]You can keep up with me on Twitter.

References

Visible links
1. https://twitter.com/AbdulHai23

AskEMA, Agencia Europea de Medicamentos

Dear Sir/Madam

Re: ASK-28953 Appeal received on 28 March 2017

Thank you for submitting your request.

This is an automated response to confirm that we have received your
request; please do not respond to this message.

We endeavour to provide a response to all information enquiries (RFI)
within 2 months according to [1]The European Medicines Agency Code of Good
Administrative Behaviour.

Concerning requests for access to documents (ATD), your enquiry will be
processed according to [2]Regulation (EC) No 1049/2001. .
For more information on ATD please refer to our guide on access to
unpublished documents:
[3]http://www.ema.europa.eu/ema/index.jsp?c...

This automated response is not an acknowledgement of receipt or
registration for the purpose of the ATD process. Such
acknowledgment/registration will be issued separately following
validation.

Should you need to contact us, please always use in the title of your
email, the reference number ASK-28953, which has been allocated to your
request.

Kind regards

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [4]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. http://www.ema.europa.eu/docs/en_GB/docu...
2. http://www.europarl.europa.eu/RegData/PD...
3. http://www.ema.europa.eu/ema/index.jsp?c...
4. http://www.ema.europa.eu/contact

ocultar partes citadas

AskEMA, Agencia Europea de Medicamentos

Re: EMA request reference ASK-28953

Dear Mr Hai,

Thank you for your email.

Your initial request ASK- [1]ASK-28403 was handled as a Request for
Information (RFI) since you requested information and did not request
access to one or more documents.

More specifically, you requested:
a) “Can you publish all information sent to staff in regards to Brexit?”
and
b) “Can you publish any planning documents in regards to Brexit?”

According to SOP/H/0019 “Standard operating Procedure for Handling of
requests for information” published by the EMA, "Request for information"
shall mean external requests requiring an answer from the Agency and not
falling within the scope of "Access to documents" (covered by
SOP/EMA/0041). Your aforementioned request therefore constituted a request
for information and not a request for access to documents.

Requests for information are handled in accordance with the European
Medicines Agency Code of Good Administrative Behaviour. Please see the
Standard operating Procedure for Handling of requests for information
(SOP/EMA/0019):
[2]http://www.ema.europa.eu/docs/en_GB/docu...

There is no appeal procedure in Requests for information.

Therefore, if an access to document is intended, please submit to the
Agency an access to documents request with a clear indication of the
documents you request access to, by using the web form via the link below:
[3]http://www.ema.europa.eu/ema/index.jsp?c...

Further to the receipt of a clear access to documents request, the Agency
will process it in accordance to Regulation (EC) No 1049/2001 and the
Agency’s “Guide on access to unpublished documents” EMA/304162/2014:
[4]http://www.ema.europa.eu/docs/en_GB/docu...

Thank you for considering the above.

Sincerely Yours,

EMA Access to Documents

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [5]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

--------------------------------------------------------------------------

Original request: Appeal

Dear European Medicines Agency, Please pass this on to the person who
reviews confirmatory applications. I am filing the following confirmatory
application with regards to my access to documents request 'Brexit'. I
believe that a blanket decision has been made not to publish information.
Some of it should be in the public domain. Also I note that no legal
reasons were given. A full history of my request and all correspondence is
available on the Internet at this address:
https://www.asktheeu.org/en/request/brex... Yours faithfully, Abdul Hai

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. Brexit
http://askema.eudra.org/browse/ASK-28403
2. http://www.ema.europa.eu/docs/en_GB/docu...
3. http://www.ema.europa.eu/ema/index.jsp?c...
4. http://www.ema.europa.eu/docs/en_GB/docu...
5. http://www.ema.europa.eu/contact

ocultar partes citadas

AskEMA, Agencia Europea de Medicamentos

Dear Sir/Madam

Re: ASK-29006 Brexit received on 29 March 2017

Thank you for submitting your request.

This is an automated response to confirm that we have received your
request; please do not respond to this message.

We endeavour to provide a response to all information enquiries (RFI)
within 2 months according to [1]The European Medicines Agency Code of Good
Administrative Behaviour.

Concerning requests for access to documents (ATD), your enquiry will be
processed according to [2]Regulation (EC) No 1049/2001. .
For more information on ATD please refer to our guide on access to
unpublished documents:
[3]http://www.ema.europa.eu/ema/index.jsp?c...

This automated response is not an acknowledgement of receipt or
registration for the purpose of the ATD process. Such
acknowledgment/registration will be issued separately following
validation.

Should you need to contact us, please always use in the title of your
email, the reference number ASK-29006, which has been allocated to your
request.

Kind regards

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [4]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. http://www.ema.europa.eu/docs/en_GB/docu...
2. http://www.europarl.europa.eu/RegData/PD...
3. http://www.ema.europa.eu/ema/index.jsp?c...
4. http://www.ema.europa.eu/contact

ocultar partes citadas

AskEMA, Agencia Europea de Medicamentos

Dear Sir/Madam

Re: ASK-29700 ASK-29006 received on 21 April 2017

Thank you for submitting your request.

This is an automated response to confirm that we have received your
request; please do not respond to this message.

We endeavour to provide a response to all information enquiries (RFI)
within 2 months according to [1]The European Medicines Agency Code of Good
Administrative Behaviour.

Concerning requests for access to documents (ATD), your enquiry will be
processed according to [2]Regulation (EC) No 1049/2001. .
For more information on ATD please refer to our guide on access to
unpublished documents:
[3]http://www.ema.europa.eu/ema/index.jsp?c...

This automated response is not an acknowledgement of receipt or
registration for the purpose of the ATD process. Such
acknowledgment/registration will be issued separately following
validation.

Should you need to contact us, please always use in the title of your
email, the reference number ASK-29700, which has been allocated to your
request.

Kind regards

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [4]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. http://www.ema.europa.eu/docs/en_GB/docu...
2. http://www.europarl.europa.eu/RegData/PD...
3. http://www.ema.europa.eu/ema/index.jsp?c...
4. http://www.ema.europa.eu/contact

ocultar partes citadas

AskEMA, Agencia Europea de Medicamentos

Re: EMA request reference ASK-29700

Dear Mr Hai,
Thank you for contacting the European Medicines Agency regarding the
acknowledgement of receipt of your request for Access to Documents,
reference [1]ASK-29700.
Please note that the acknowledgement was sent to you on 30th March 2017.
The request itself is being processed in accordance with Regulation (EC)
No 1049/2001.
Kind regards,

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [2]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

--------------------------------------------------------------------------

Original request: ASK-29006

I have not got an acknowledgment yet

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. ASK-29006
http://askema.eudra.org/browse/ASK-29700
2. http://www.ema.europa.eu/contact

ocultar partes citadas

AskEMA, Agencia Europea de Medicamentos

Re: EMA request reference ASK-29006

Dear Mr Hai,

I would be grateful if you could provide us with a different e-mail
address to reply to your request.

The Agency uses a secure encrypted system to send replies to requests for
documents and that system does not recognise the e-mail address you
provided from asktheeu.org.

Please note that the e-mail should be submitted via our webform
([1]http://www.ema.europa.eu/ema/index.jsp?c...),
as replies to thios e-mails are not monitored.

Many thanks in advance.

Kind regards,

Document Access and Publication Service

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [2]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

--------------------------------------------------------------------------

Original request: Brexit docs to staff and planning docs

Dear European Medicines Agency, Under the right of access to documents in
the EU treaties, as developed in Regulation 1049/2001, I am requesting
documents which contain the following information: Can you publish all
information sent to staff in regards to Brexit? Can you publish any
planning documents in regards to Brexit? Yours faithfully, Abdul Hai

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. http://www.ema.europa.eu/ema/index.jsp?c...
2. http://www.ema.europa.eu/contact

ocultar partes citadas

Abdul Hai dejó un comentario ()

I will provide them with a different email address but forward all correspondence I get from them here.

Abdul Hai dejó un comentario ()

I have given them a different email address now.

I have never been treated like this in the UK.

 
[1]You can keep up with me on Twitter.

----- Forwarded Message -----
From: AskEMA <[email address]>
To: [email address]
Sent: Wednesday, 26 April 2017, 11:58
Subject: Ask EMA - (ASK-29842) ASK-29006
Dear Sir/Madam

Re: ASK-29842 ASK-29006 received on 26 April 2017

Thank you for submitting your request.

This is an automated response to confirm that we have received your
request; please do not respond to this message.

We endeavour to provide a response to all information enquiries (RFI)
within 2 months according to [2]The European Medicines Agency Code of Good
Administrative Behaviour.

Concerning requests for access to documents (ATD), your enquiry will be
processed according to [3]Regulation (EC) No 1049/2001. .
For more information on ATD please refer to our guide on access to
unpublished documents:
[4]http://www.ema.europa.eu/ema/index.jsp?c...

This automated response is not an acknowledgement of receipt or
registration for the purpose of the ATD process. Such
acknowledgment/registration will be issued separately following
validation.

Should you need to contact us, please always use in the title of your
email, the reference number ASK-29842, which has been allocated to your
request.

Kind regards

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [5]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. https://twitter.com/AbdulHai23
2. http://www.ema.europa.eu/docs/en_GB/docu...
3. http://www.europarl.europa.eu/RegData/PD...
4. http://www.ema.europa.eu/ema/index.jsp?c...
5. http://www.ema.europa.eu/contact

ocultar partes citadas

Dear European Ombudsman,
The European Medicines Agency is trying to stop me from obtaining
information using asktheeu.org. 
I have used a similar site for the UK and no public body has refused to
answer my questions using the site. The ICO in fact makes them answer
using the whatdotheyknow.com site. 
 
[1]You can keep up with me on Twitter.

References

Visible links
1. https://twitter.com/AbdulHai23

 
[1]You can keep up with me on Twitter.

----- Forwarded Message -----
From: "[email address]" <[email address]>
To: [email address]
Sent: Thursday, 27 April 2017, 15:55
Subject: EudraLink - ASK-29006 - response to your request for documents
+++++++++++++++++++++++++++++++++++++++++++++
You have been sent a package by "European Medicines Agency"
<[2][email address]>
To retrieve your package use the hyperlink below
[3]https://eudralink.ema.europa.eu/dl.php?d...
The package will expire on Mon, 26 Jun 2017 15:55:54 +0100
HOW TO PICK UP YOUR PACKAGE:
If the Web address above is highlighted, click on it to open a browser
window. You will automatically be taken to the package.
If the Web address above is not highlighted, follow these steps:
- Open a Web browser window.
- Copy and paste the entire Web address into the "location" or "address"
bar of the browser.
- Press enter.
Once you arrive at the Web page, you can access the package.
+++++++++++++++++++++++++++++++++++++++++++++

References

Visible links
1. https://twitter.com/AbdulHai23
2. mailto:[email address]
3. https://eudralink.ema.europa.eu/dl.php?d...

ocultar partes citadas

 
[1]You can keep up with me on Twitter.

----- Forwarded Message -----
From: AskEMA <[email address]>
To: [email address]
Sent: Thursday, 27 April 2017, 16:00
Subject: Ask EMA - (ASK-29842) ASK-29006
Re: EMA request reference ASK-29842

Dear Mr Hai,
many thanks for submitting an alternative e-mail address so that we can
reply to your request [2]ASK-29006.
A message has just been sent by Eudralink replying to request [3]ASK-29006
and I would be grateful if you could confirm reception of that message
upon receipt.
I do apologise for any inconvenience that the delay caused by this
technical problem may have caused.
Kind regards,
Document Access and Publication Service

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [4]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

--------------------------------------------------------------------------

Original request: ASK-29006

I am using a different email as requested.

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. https://twitter.com/AbdulHai23
2. Brexit docs to staff and planning docs
http://askema.eudra.org/browse/ASK-29006
3. Brexit docs to staff and planning docs
http://askema.eudra.org/browse/ASK-29006
4. http://www.ema.europa.eu/contact

ocultar partes citadas

 
[1]You can keep up with me on Twitter.

----- Forwarded Message -----
From: AskEMA <[email address]>
To: [email address]
Sent: Thursday, 4 May 2017, 13:35
Subject: Ask EMA - (ASK-30070) ASK-29006
Dear Sir/Madam

Re: ASK-30070 ASK-29006 received on 4 May 2017

Thank you for submitting your request.

This is an automated response to confirm that we have received your
request; please do not respond to this message.

We endeavour to provide a response to all information enquiries (RFI)
within 2 months according to [2]The European Medicines Agency Code of Good
Administrative Behaviour.

Concerning requests for access to documents (ATD), your enquiry will be
processed according to [3]Regulation (EC) No 1049/2001. .
For more information on ATD please refer to our guide on access to
unpublished documents:
[4]http://www.ema.europa.eu/ema/index.jsp?c...

This automated response is not an acknowledgement of receipt or
registration for the purpose of the ATD process. Such
acknowledgment/registration will be issued separately following
validation.

Should you need to contact us, please always use in the title of your
email, the reference number ASK-30070, which has been allocated to your
request.

Kind regards

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [5]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines
Agency.
________________________________________________________________________

References

Visible links
1. https://twitter.com/AbdulHai23
2. http://www.ema.europa.eu/docs/en_GB/docu...
3. http://www.europarl.europa.eu/RegData/PD...
4. http://www.ema.europa.eu/ema/index.jsp?c...
5. http://www.ema.europa.eu/contact

ocultar partes citadas

 
[1]You can keep up with me on Twitter.

----- Forwarded Message -----
From: "[email address]" <[email address]>
To: [email address]
Sent: Friday, 19 May 2017, 16:22
Subject: EudraLink - ASK-29006 - letter to requester - confirmatory
application
+++++++++++++++++++++++++++++++++++++++++++++
You have been sent a package by "European Medicines Agency"
<[2][email address]>
To retrieve your package use the hyperlink below
[3]https://eudralink.ema.europa.eu/dl.php?d...
The package will expire on Tue, 18 Jul 2017 16:22:25 +0100
HOW TO PICK UP YOUR PACKAGE:
If the Web address above is highlighted, click on it to open a browser
window. You will automatically be taken to the package.
If the Web address above is not highlighted, follow these steps:
- Open a Web browser window.
- Copy and paste the entire Web address into the "location" or "address"
bar of the browser.
- Press enter.
Once you arrive at the Web page, you can access the package.
+++++++++++++++++++++++++++++++++++++++++++++

References

Visible links
1. https://twitter.com/AbdulHai23
2. mailto:[email address]
3. https://eudralink.ema.europa.eu/dl.php?d...

ocultar partes citadas

Abdul Hai dejó un comentario ()

I have appealed to the European Ombudsman.

Abdul Hai dejó un comentario ()

Abdul Hai dejó un comentario ()

Can't really go to Ombudsman as I don't have the documents.

Abdul Hai dejó un comentario ()

I may be able to get some more information from this one. https://www.asktheeu.org/en/request/relo...

No sabemos si la última respuesta a esta solicitud contiene información o no – si eres Abdul Hai por favor abre una sesión y háznoslo saber.